C07J 3/00
Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17
Official title: Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
C07J3/00 (Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17) appears on 196 US grants and 155 published applications in this corpus.
Search patents in C07J- Granted patents
- 196
- Published applications
- 155
- Assignees
- 83
- Inventors
- 402
- Latest grant
- 30 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 5 | 0 |
| 1977 | 1 | 0 |
| 1978 | 3 | 0 |
| 1979 | 1 | 0 |
| 1980 | 7 | 0 |
| 1981 | 6 | 0 |
| 1982 | 4 | 0 |
| 1983 | 2 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 3 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 4 | 0 |
| 1990 | 3 | 0 |
| 1991 | 5 | 0 |
| 1992 | 5 | 0 |
| 1993 | 4 | 0 |
| 1994 | 3 | 0 |
| 1995 | 6 | 0 |
| 1996 | 4 | 0 |
| 1997 | 10 | 0 |
| 1998 | 7 | 0 |
| 1999 | 12 | 0 |
| 2000 | 4 | 0 |
| 2001 | 4 | 0 |
| 2002 | 2 | 6 |
| 2003 | 6 | 7 |
| 2004 | 5 | 13 |
| 2005 | 3 | 14 |
| 2006 | 3 | 5 |
| 2007 | 5 | 5 |
| 2008 | 2 | 9 |
| 2009 | 4 | 6 |
| 2010 | 4 | 4 |
| 2011 | 1 | 2 |
| 2012 | 2 | 1 |
| 2013 | 3 | 6 |
| 2014 | 2 | 6 |
| 2015 | 1 | 5 |
| 2016 | 9 | 13 |
| 2017 | 8 | 7 |
| 2018 | 2 | 6 |
| 2019 | 6 | 4 |
| 2020 | 5 | 6 |
| 2021 | 2 | 9 |
| 2022 | 5 | 4 |
| 2023 | 6 | 8 |
| 2024 | 3 | 4 |
| 2025 | 2 | 3 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders30 Dec 2025US 12,509,487 B2The Texas A&M University System
- 19-nor C3,3-disubstituted C21-n-pyrazolyl steroids and methods of use thereof21 Jan 2025US 12,201,640 B2Sage Therapeutics, Inc.
- Neuroactive steroids, compositions, and uses thereof29 Oct 2024US 12,129,275 B2Sage Therapeutics, Inc.
- Compositions and methods for treating CNS disorders20 Aug 2024US 12,065,463 B2Sage Therapeutics, Inc.
- Compositions and methods for treating CNS disorders2 Apr 2024US 11,945,836 B2Sage Therapeutics, Inc.
- Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders30 Apr 2026US 2026/0116913 A1The Texas A&M University System
- Compounds and methods for the treatment of dermal and ocular disorders26 Feb 2026US 2026/0055110 A1Azura Ophthalmics Ltd.
- 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof16 Oct 2025US 2025/0319106 A1Sage Therapeutics, Inc.
- Neuroactive steroids, compositions, and uses thereof14 Aug 2025US 2025/0257092 A1Sage Therapeutics, Inc.
- Compositions and methods for treating cns disorders6 Feb 2025US 2025/0042934 A1Sage Therapeutics, Inc.
Most cited
By later US patents
- 4-Aza-17.beta.-substituted-5.alpha.-androstan-3-one-reductase inhibitors159US 4,377,584 AMerck & Co., Inc. · 1983
- Androstane carbothioates130US 4,335,121 AGlaxo Group Limited · 1982
- Soft steroids having anti-inflammatory activity100US 4,996,335 A1991
- Methods for controlling ocular hypertension with angiostatic steroids86US 4,876,250 AAlcon Laboratories, Inc. · 1989
- Angiostatic steroids and methods and compositions for controlling ocular hypertension78US 5,371,078 AAlcon Laboratories, Inc. · 1994